Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients

Pei-Jing Li, Kai-Xin Li, Ting Jin, Hua-Ming Lin, Jia-Ben Fang, Shuang-Yan Yang, Wei Shen, Jia Chen, Jiang Zhang, Xiao-Zhong Chen, Ming Chen, Yuan-Yuan Chen, Pei-Jing Li, Kai-Xin Li, Ting Jin, Hua-Ming Lin, Jia-Ben Fang, Shuang-Yan Yang, Wei Shen, Jia Chen, Jiang Zhang, Xiao-Zhong Chen, Ming Chen, Yuan-Yuan Chen

Abstract

Purpose: To explore risk factors for severe acute oral mucositis of nasopharyngeal carcinoma (NPC) patients receiving chemo-radiotherapy, build predictive models and determine preventive measures.

Methods and materials: Two hundred and seventy NPC patients receiving radical chemo-radiotherapy were included. Oral mucosa structure was contoured by oral cavity contour (OCC) and mucosa surface contour (MSC) methods. Oral mucositis during treatment was prospectively evaluated and divided into severe mucositis group (grade ≥ 3) and non-severe mucositis group (grade < 3) according to RTOG Acute Reaction Scoring System. Nineteen clinical features and nineteen dosimetric parameters were included in analysis, least absolute shrinkage and selection operator (LASSO) logistic regression model was used to construct a risk score (RS) system.

Results: Two predictive models were built based on the two delineation methods. MSC based model is more simplified one, it includes body mass index (BMI) classification before radiation, retropharyngeal lymph node (RLN) area irradiation status and MSC V55%, RS = -1.480 + (0.021 × BMI classification before RT) + (0.126 × RLN irradiation) + (0.052 × MSC V55%). The cut-off of MSC based RS is -1.011, with an area under curve (AUC) of 0.737 (95%CI: 0.672-0.801), a specificity of 0.595 and a sensitivity of 0.786. OCC based model involved more variables, RS= -4.805+ (0.152 × BMI classification before RT) + (0.080 × RT Technique) + (0.097 × Concurrent Nimotuzumab) + (0.163 × RLN irradiation) + (0.028 × OCC V15%) + (0.120 × OCC V60%). The cut-off of OCC based RS is -0.950, with an AUC of 0.767 (95%CI: 0.702-0.831), a specificity of 0.602 and a sensitivity of 0.819. Analysis in testing set shown higher AUC of MSC based model than that of OCC based model (AUC: 0.782 vs 0.553). Analysis in entire set shown AUC in these two method-based models were close (AUC: 0.744 vs 0.717).

Conclusion: We constructed two risk score predictive models for severe oral mucositis based on clinical features and dosimetric parameters of nasopharyngeal carcinoma patients receiving chemo-radiotherapy. These models might help to discriminate high risk population in clinical practice that susceptible to severe oral mucositis and individualize treatment plan to prevent it.

Keywords: nasopharyngeal carcinoma; dosimetric parameter; preventive measures; radiation-induced oral mucositis; radiotherapy.

Copyright © 2020 Li, Li, Jin, Lin, Fang, Yang, Shen, Chen, Zhang, Chen, Chen and Chen.

Figures

Figure 1
Figure 1
(A) Box plots of dose-volume objectives distributions. Mean values are indicated by the horizontal lines within boxes and median values are represented by the diamonds. Severe oral mucositis group (grade ≥ 3) and non-severe oral mucositis group (grade = 1, 2) data were drawn as red forward diagonal and blue backward diagonal boxes respectively. Note: *Statistically significant at p=0.05 level. (B) Area under curve (AUC) of all the dose-volume objectives under both oral cavity contour (OCC) (red solid line) and mucosa surface contour (MSC) (blue dashed line) methods. Each AUC is acquired from the ROC curve of each objective. Most dose-volume objectives under MSC method show better performance (higher AUC) than OCC method in terms of predicting severe oral mucositis.
Figure 2
Figure 2
(A, F) LASSO coefficient profiles of 19 clinical features and 19 MSC and OCC based dosimetric parameters; (B, G) Ten-fold cross-validation for tuning parameter selection in MSC and OCC based LASSO model. (C–E, H–J) ROC curve for MSC and OCC based model: (C, H) Training group, (D, I) Testing group, (E, J) Entire group. The point on the curve is cutoff value for RS and the following bracket contains specificity and sensitivity. Abbreviation: RS, risk score; OCC, oral cavity contouring; MSC, mucosa surface contouring; AUC, area under curve; CI, confidence interval.
Figure 3
Figure 3
Patients distribution of V10% and V15% by using TOMO and IMRT. (A) MSC V10%, (B) MSC V15%, (C) OCC V10%, (D) OCC V15%. Abbreviations: OCC, oral cavity contouring; MSC, mucosa surface contouring.
Figure 4
Figure 4
Computed tomography (CT) scan of a nasopharyngeal carcinoma patient with mucosal surface contours (MSC) (up, area filled with blue) and oral cavity contours (OCC) (down, area filled with brown). MSC involves the mucosal surface while OCC encompass more solid tissue, like tongue, maxillary bone, etc. The green line and pink line are isodose curve of 50Gy and 55Gy respectively. Abbreviations: OCC, oral cavity contouring; MSC, mucosa surface contouring.

References

    1. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. 10.3322/caac.21492
    1. Li K, Yang L, Hu Qy, Chen Xz, Chen M, Chen Y. Oral Mucosa Dose Parameters Predicting Grade ≥3 Acute Toxicity in Locally Advanced Nasopharyngeal Carcinoma Patients Treated With Concurrent Intensity-Modulated Radiation Therapy and Chemotherapy: An Independent Validation Study Comparing Oral Cavity vers. Transl Oncol (2017) 10:752–9. 10.1016/j.tranon.2017.06.011
    1. Tan T, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2015) 91:952–60. 10.1016/j.ijrobp.2015.01.002
    1. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol (2016) 17:1509–20. 10.1016/S1470-2045(16)30410-7
    1. Duncan GG, Epstein JB, Tu D, El Sayed, Bezjak A, Ottaway J, et al. Quality fo life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck (2005) 27(5):421–8. 10.1002/hed.20162
    1. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys (2000) 47:1–12. 10.1016/S0360-3016(99)00558-1
    1. Russo G, Haddad R, Posner M, Machtay M. Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer. Oncologist (2008) 13:886–98. 10.1634/theoncologist.2008-0024
    1. Kelly C, Paleri V, Downs C, Shah R. Deterioration in quality of life and depressive symptoms during radiationtherapy for head and neck cancer. Otolaryngol Head Neck Surg (2007) 136:108–11. 10.1016/j.otohns.2006.06.1278
    1. Jin T, Li K, Li P, Huang S, Chen X. An evaluation of nutrition intervention during radiation therapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncotarget (2017) 8:83723–33. 10.18632/oncotarget.19381
    1. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol (2001) 61:223–31. 10.1016/S0167-8140(01)00429-7
    1. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol (2007) 25:4096–103. 10.1200/JCO.2007.13.3983
    1. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol (1999) 52:157–64. 10.1016/S0167-8140(99)00107-3
    1. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC = ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. Cancer (2014) 120(10):1453–61. 10.1002/cncr.28592
    1. Otter S, Schick U, Gulliford S, Lal P, Franceschini D, Newbold K, et al. Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. Radiat Oncol Biol (2015) 93:507–15. 10.1016/j.ijrobp.2015.07.2263
    1. Sanguineti G, Sormani P, Ph D, Marur S, Gunn GB, Rao N, et al. Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. Radiat Oncol Biol (2012) 83:235–42. 10.1016/j.ijrobp.2011.06.2000
    1. Harrington K. Normal tissue complication probability (NTCP ) modelling of severe acute mucositis using a novel oral mucosal surface. Clin Oncol (2017) 29:263–73. 10.1016/j.clon.2016.12.001.Normal
    1. Dean JA, Wong KH, Welsh LC, Jones A, Schick U, Kate L. Normal tissue complication probability (NTCP ) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. Radiat Oncol (2016) 120:21–7. 10.1016/j.radonc.2016.05.015.Normal
    1. Li K, Yang L, Xin P, Chen Y, Hu Q-Y, Chen X-Z, et al. Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy. Oral Oncol (2017) 72:32–7. 10.1016/j.oraloncology.2017.06.026
    1. Liu Z, Zhao Y, Tang J, Zhou Y, Yang W. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget (2016) 7(17):24429–35. 10.18632/oncotarget.8225
    1. Sun Y, Yu XL, Luo W, Lee AWM, Wee JTS, Lee N, et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol (2014) 110:390–7. 10.1016/j.radonc.2013.10.035
    1. Ueno D, Sato J, Igarashi C, Ikeda S, Morita M, Shinji S, et al. Accuracy of oral mucosal thickness measurements using spiral computed tomography. J Periodontol (2011) 82(6):829–36. 10.1902/jop.2010.100160
    1. Li CJ, Wang SZ, Wang SY, Zhang YP. Assessment of the effect of local application of amifostine on acute radiation-induced oral mucositis in guinea pigs. J Radiat Res (2014) 55:847–54. 10.1093/jrr/rru024
    1. Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant (2002) 5:373–7. 10.1038/sj.bmt.1703394
    1. Corbel MJ, Tolari F, Yadava VK. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications. Lancet (2004) 363:157–63. 10.1016/S0140-6736(03)15268-3
    1. Yao J-J, Zhang L-L, Gao T-S, Peng Y-L, Lawrence WR, Zhang W-J, et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol Ther (2018) 19:1102–7. 10.1080/15384047.2018.1491501
    1. Zhi-Qiang W, Qi M, Ji-Bin L, Rui Y, You-Ping L, Rui S, et al. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer (2019) 19:1122. 10.1186/s12885-019-6156-5
    1. Wang F, Jiang C, Ye Z, Sun Q, Liu T. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma Patient characteristics. Oncotarget (2017) 8:75544–56. 10.18632/oncotarget.17357
    1. Musha A, Fukata K, Saitoh J, Shirai K, Abe T, Mizukami T, et al. Tongue surface model can predict radiation tongue mucositis due to intensity- modulated radiation therapy for head and neck cancer. Int J Oral Maxillofac Surg (2020) 49(1):44–50. 10.1016/j.ijom.2019.06.012
    1. Lee H, Ahn YC, Oh D, Nam H, Noh JM, Park SY. Tumor volume reduction rate during adaptive radiation therapy as a prognosticator for nasopharyngeal cancer. Cancer Res Treat (2016) 48:537–45. 10.4143/crt.2015.081
    1. Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol (2011) 98:23–7. 10.1016/j.radonc.2010.10.009
    1. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest (2017) 127:1–4. 10.1172/JCI92035
    1. Lee AW, Tong W, Ji J, Poh SS, Chan Y, Alhussain H, et al. International guideline for the delineation of the clinical target volumes (CTV ) for nasopharyngeal carcinoma. Radiother Oncol (2017) 126(1):1–12. 10.1016/j.radonc.2017.10.032
    1. Liu LZ, Zhang GY, Xie CM, Liu XW, Cui CY, Li L. Magnetic resonance imaging of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: Patterns of spread. Int J Radiat Oncol Biol Phys (2006) 66:721–30. 10.1016/j.ijrobp.2006.05.054
    1. Wang XS, Hu CS, Ying HM, Zhou ZR, Ding JH, Feng Y. Patterns of Retropharyngeal Node Metastasis in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys (2009) 73:194–201. 10.1016/j.ijrobp.2008.03.067
    1. King AD, Ahuja AT, Leung SF, Lam WWM, Teo P, Chan YL, et al. Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck (2000) 22:275–81. 10.1002/(SICI)1097-0347(200005)22:3<275::AID-HED10>;2-N
    1. Meade S, Hons M, Sanghera P, Mcconkey C, Fowler J, Fountzilas G, et al. Revising the Radiobiological Model of Synchronous Chemotherapy in Head-and-Neck Cancer: A New Analysis Examining Reduced Weighting of Accelerated Repopulation. Radiat Oncol Biol (2013) 86:157–63. 10.1016/j.ijrobp.2012.11.023
    1. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. Int J Radiat Oncol Biol Phys (2007) 68:1110–20. 10.1016/j.ijrobp.2007.01.053
    1. Li P, Li K, Lin H, Fang J, Yang S, Shen W, et al. Predictive Model for Oral Mucositis of Nasopharyngeal Carcinoma Patients Receiving Chemo-radiotherapy. Res Sq (2020) 1–23. 10.21203/-33706/v1

Source: PubMed

3
S'abonner